Assembly Biosciences, Inc. (ASMB)

Assembly Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	19.84	52.42	45.63	59.44	46.73
Short-Term Investments	110.41	39.19	101	156.97	227.31
Cash & Cash Equivalents	130.25	91.61	146.63	216.41	274.04
Cash Growth	42.18%	-37.52%	-32.25%	-21.03%	25.66%
Receivables	0.04	0.94	0.34	1.23	3.37
Other Current Assets	3.5	4.41	7.24	6.85	5.36
Total Current Assets	133.79	96.97	154.2	224.49	282.78
Property, Plant & Equipment	2.72	3.94	7.18	10.73	13.81
Long-Term Investments	0	0	27.97	0	0
Goodwill and Intangibles	0	0	0	41.64	41.64
Other Long-Term Assets	0.31	0.89	1.7	6.39	1.68
Total Long-Term Assets	3.04	4.83	36.86	58.76	57.13
Total Assets	136.82	101.79	191.06	283.25	339.91
Accounts Payable	0.46	2.49	2.66	4.6	1.73
Deferred Revenue	86.29	2.73	2.73	8.99	37.05
Current Debt	1.22	3.36	3.15	3.4	3.19
Other Current Liabilities	-48.75	7.71	7.53	7.44	-17.53
Total Current Liabilities	39.23	16.3	16.07	24.43	24.44
Long-Term Debt	1.12	0.1	3.33	6.73	9.08
Other Long-Term Liabilities	55.38	2.73	2.73	11.52	33.17
Total Long-Term Liabilities	56.5	2.83	6.06	18.24	42.25
Total Liabilities	95.73	19.13	22.13	42.68	66.69
Total Debt	2.34	3.47	6.48	10.13	12.27
Debt Growth	-32.41%	-46.49%	-36.06%	-17.44%	-
Retained Earnings	-785.75	-724.52	-631.43	-501.57	-439.42
Comprehensive Income	-0.08	-0.8	-0.42	-0.27	-0.2
Shareholders' Equity	41.1	82.66	168.93	240.58	273.22
Net Cash / Debt	127.91	88.15	140.15	206.28	261.78
Net Cash / Debt Growth	45.11%	-37.11%	-32.06%	-21.20%	20.04%
Net Cash Per Share	27.94	21.85	38.86	69.87	119.63
Working Capital	94.56	80.67	138.13	200.06	258.34
Book Value Per Share	8.98	20.49	46.84	81.49	124.86

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).